1, 2025, or on the plan sponsor's 2025 renewal date
Leveraging the natural effects of GLP-1, these agonists encourage weight loss through various pathways, including enhancing satiety and promoting better glycemic control
They can be secondary to a reduced MTHFR activity ( 38 mol/L, according to Graham et al, 1997)
This layered oversight guideline-informed thresholds, personalized dosing, and continuous remote monitoring supports both efficacy and patient safety in virtual GLP-1 management
When acetaminophen is taken in toxic amounts, the liver produces a damaging metabolite called NAPQI
the numbers look larger but the design cannot support a head-to-head claim.9 In paediatric type 1 there are no Phase 3 trials at all, a gap ISPAD 2024 flags explicitly.6 Longer, larger AID-era trials with hard outcomes, paediatric data, and head-to-head tirzepatide RCTs would all strengthen it